ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Endowing Flexibility of Alveolar Type II Cells to Recapitulate Development From Lung Bud to Alveoli.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Alveolar type 2 (AT2) cells, which originate from bud tip progenitors during lung development, maintain pulmonary homeostasis through surfactant secretion and regenerative capacity, yet their plasticity has been challenging to model in vitro, limiting their applications in disease modeling and regenerative therapy. Here, a chemically defined reprogramming strategy is developed that enables efficient conversion of adult human AT2 cells into a highly expandable alveolar progenitor-like state that, at late passages, closely resembles primitive lung bud tip epithelium. These progenitor cells robustly self-organize into three-dimensional alveolar progenitor-like organoids (APLOs), which can be further efficiently differentiated into mature alveolar-like organoids (ALOs). In vitro, ALOs serve as a physiologically relevant platform for modeling influenza A virus (IAV) infection and mounting innate immune responses characterized by interferon signaling, thereby enabling mechanistic studies of viral pathogenesis and host defense. In vivo, following intratracheal transplantation into lung-injured mice, APLO-derived cells exhibit stable engraftment and differentiate into alveolar epithelial lineages, leading to improvement in pulmonary function. In summary, this study establishes an adult-derived, expandable alveolar progenitor platform generated through chemical reprogramming that recapitulates key aspects of alveolar development, disease modeling, and regenerative potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.